SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA) announced today that four preclinical abstracts highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor for the treatment of hematological malignancies, have been selected for presentation at the American Society of Hematology (ASH) annual meeting and exposition, taking place December 6-9, 2014 in San Francisco, California. Details for the presentations are as follows:
Biomarkers of Response to the Glutaminase Inhibitor CB-839 in Multiple Myeloma Cells
Abstract #3429
Andrew L. MacKinnon, Ph.D., Calithera Biosciences
Poster Session 652 Myeloma: Pathophysiology and Pre-Clinical studies, excluding Therapy: Poster II
Sunday, December 7, 2014 at 6:00-8:00 PM PST
Moscone Center, West Building, Level 1
Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839
Abstract #3439
Deepika Sharma Das, Ph.D., Dana Farber Cancer Institute
Poster Session 652 Myeloma: Pathophysiology and Pre-Clinical studies, excluding Therapy: Poster II
Sunday, December 7, 2014 at 6:00-8:00 PM PST
Moscone Center, West Building, Level 1
Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide in Preclinical Multiple Myeloma Models
Abstract #4720
Francesco Parlati, Ph.D., Calithera Biosciences
Poster Session 652 Myeloma: Pathophysiology and Pre-Clinical studies, excluding Therapy: Poster III
Monday, December 8, 2014 at 6:00-8:00 PM PST
Moscone Center, West Building, Level 1
Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia
Abstract #3763
Polina Matre, Ph.D., MD Anderson Cancer Center
Poster Session 616 Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Monday, December 8, 2014 at 6:00-8:00 PM PST
Moscone Center, North Building, Hall E
The meeting abstracts can be viewed online through the ASH website at www.hematology.org.
About Calithera Biosciences
Calithera Biosciences is a clinical-stage company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology. Calithera's lead clinical candidate, CB-839, is a first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism, and is currently being tested in patients with solid and hematological cancers. Calithera Biosciences is headquartered in South San Francisco. For more information about Calithera Biosciences, please visit www.calithera.com.